ClinicalTrials.gg
CompletedNCT02973776Updated May 9, 2017

Vasoconstriction Trial With LEO 90100 Aerosol Foam

A Phase 1 interventional study of LEO 90100 aerosol foam and Dermoval®/Dermovate® in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing betamethasone dipropionate in Psoriasis — 1 open to participants now, 1 under way, 1 of them phase 3. betamethasone dipropionate · Psoriasis.

Enrollment
24th of 29
36 · median 224
Started
2016
with 2 others
Phase 1
2 of 29
none open now
Registered
19th of 29
by date
Lead sponsor
16 of 29
LEO Pharma

Among the 29 studies testing betamethasone dipropionate in Psoriasis, this one is the 24th largest by enrollment, is one of 3 that started in 2016, is one of 2 in phase 1, and was the 19th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 29 studies testing betamethasone dipropionate in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About betamethasone dipropionate

betamethasone dipropionate: first FDA approval 1975 (DIPROSONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing betamethasone dipropionate in Psoriasis, or all of them as a file.
02

Study summary

Vasoconstriction study with LEO 90100

Read the detailed description

This study compares the pharmacodynamic activity of LEO 90100 with Dermovate cream, Diprosone ointment, Elocon cream, Locoid ointment and LEO 90100 vehicle using a human skin blanching test

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects demonstrating adequate vasoconstriction to Diprosone® ointment within 15 days prior to dosing (unoccluded application of Diprosone® ointment for 4-6 hours must show a visual score of skin blanching of at least one unit (visual scale (0-4)).
  • Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).

Exclusion criteria

Exclusion Criteria:

  • Abnormal pigmentation of the skin or skin type that could, in any way, confound interpretation of the trial results (skin type V and VI on the Fitzpatrick scale).
  • Female subjects who are breastfeeding.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    LEO 90100 aerosol foam

    LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.

    Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle

  • Active comparator
    Dermoval®/Dermovate®

    Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.

    Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle

  • Active comparator
    Diprosone®

    Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.

    Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle

  • Active comparator
    Elocon®

    Elocon® mometasone furoate 0.1% cream Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.

    Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle

  • Active comparator
    Locoid®

    Locoid® hydrocortisone-17-butyrate 0.1% ointment Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.

    Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle

  • Placebo comparator
    LEO 90100 foam vehicle

    LEO 90100 foam vehicle Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.

    Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Mean of two visual skin blanching scores for each treatment measured 2 hours after 16 hours application under non-occlusive conditions

    Time frame: 18 hours

07

Study locations

1 site
  • CPCAD
    Nice, Cedex 06202, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Nov 25, 2016
Start
Dec 2016
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
May 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02973776
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Nov 25, 2016
Start date
Dec 2016
Primary completion
Feb 2017
Completion
Feb 2017
Last update
May 9, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LEO 90100 · Betamethasone dipropionate · Mometasone Furoate · Hydrocortisone butyrate

Start the discussion